Novo Nordisk A/S (NVO)vsRLX Technology Inc (RLX)
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
RLX
RLX Technology Inc
$2.21
+2.31%
CONSUMER DEFENSIVE · Cap: $2.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 8444% more annual revenue ($309.06B vs $3.62B). NVO leads profitability with a 33.1% profit margin vs 25.5%. NVO trades at a lower P/E of 10.4x. RLX earns a higher WallStSmart Score of 68/100 (B-).
NVO
Buy55
out of 100
Grade: C
RLX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Margin of Safety
+47.9%
Fair Value
$4.68
Current Price
$2.21
$2.47 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Reasonable price relative to book value
Revenue surging 46.8% year-over-year
Earnings expanding 81.9% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
ROE of 5.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bull Case : RLX
The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : RLX
The primary concerns for RLX are Return on Equity.
Key Dynamics to Monitor
NVO profiles as a declining stock while RLX is a growth play — different risk/reward profiles.
RLX carries more volatility with a beta of 1.23 — expect wider price swings.
RLX is growing revenue faster at 46.8% — sustainability is the question.
RLX generates stronger free cash flow (358M), providing more financial flexibility.
Bottom Line
RLX scores higher overall (68/100 vs 55/100), backed by strong 25.5% margins and 46.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
RLX Technology Inc
CONSUMER DEFENSIVE · TOBACCO · China
RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?